Mark Edwards Net Worth

The estimated Net Worth of Mark G Edwards is at least $285 Tausend dollars as of 12 November 2019. Mr. Edwards owns over 25,000 units of Acelrx Pharmaceuticals Inc stock worth over $209,625 and over the last 13 years he sold ACRX stock worth over $0. In addition, he makes $75,004 as Independent Director at Acelrx Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Edwards ACRX stock SEC Form 4 insiders trading

Mark has made over 13 trades of the Acelrx Pharmaceuticals Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 25,000 units of ACRX stock worth $44,500 on 12 November 2019.

The largest trade he's ever made was buying 40,000 units of Acelrx Pharmaceuticals Inc stock on 7 May 2015 worth over $125,200. On average, Mark trades about 9,600 units every 117 days since 2011. As of 12 November 2019 he still owns at least 243,750 units of Acelrx Pharmaceuticals Inc stock.

You can see the complete history of Mr. Edwards stock trades at the bottom of the page.

Mark Edwards biography

Mark G. Edwards serves as Independent Director of the Company. Mr. Edwards is Managing Director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. Since February 2017, Mr. Edwards has also served on the board of directors of Scripps Research Institute, a non-profit medical research facility. From July 2008 until December 2010, he was Managing Director and a Principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu, an audit and financial consulting services firm. Mr. Edwards was previously the Managing Director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California, from 1988 until the sale of Recap to Deloitte in 2008. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation, a biotechnology company. He received his B.A. and M.B.A. degrees from Stanford University. Mr. Edwards’ financial and business expertise, including his background as a business advisor to pharmaceutical and biotechnology companies, provides him with the qualifications and skills to serve as a director.

What is the salary of Mark Edwards?

As the Independent Director of Acelrx Pharmaceuticals Inc, the total compensation of Mark Edwards at Acelrx Pharmaceuticals Inc is $75,004. There are 9 executives at Acelrx Pharmaceuticals Inc getting paid more, with Vincent Angotti having the highest compensation of $2,125,050.

How old is Mark Edwards?

Mark Edwards is 62, he's been the Independent Director of Acelrx Pharmaceuticals Inc since 2011. There are 4 older and 9 younger executives at Acelrx Pharmaceuticals Inc. The oldest executive at Acelrx Pharmaceuticals Inc is Lawrence G. Hamel, 69, who is the Consultant.

What's Mark Edwards's mailing address?

Mark's mailing address filed with the SEC is C/O ACELRX PHARMACEUTICALS, INC., 25821 INDUSTRIAL BLVD., SUITE 400, HAYWARD, CA, 94545.

Insiders trading at Acelrx Pharmaceuticals Inc

Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... und Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.

What does Acelrx Pharmaceuticals Inc do?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Complete history of Mr. Edwards stock trades at Acelrx Pharmaceuticals Inc

Acelrx Pharmaceuticals Inc executives and stock owners

Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Vincent Angotti,
  Chief Executive Officer, Director
• Pamela Palmer,
  Co-Founder, Director, Chief Medical Officer
• Raffi Asadorian,
  Chief Financial Officer
• Vincent J. Angotti,
  CEO & Director
• Badri Dasu,
  Chief Engineering Officer
• Dr. Pamela Pierce Palmer,
  Co-Founder, Chief Medical Officer & Director
• Raffi Mark Asadorian,
  Chief Financial Officer
• Anil N. Dasu,
  Chief Engineering Officer
• Adrian Adams,
  Independent Chairman of the Board
• Mark Edwards,
  Independent Director
• Stephen Hoffman,
  Independent Director
• Mark Wan,
  Independent Director
• Richard Afable,
  Independent Director
• Howard Rosen,
  Independent Director
• Lawrence G. Hamel,
  Consultant
• C Steven Hoffman,
  Director
• Advisors Llcperceptive Life...,
  
• Lawrence G Hamel,
  Chief Development Officer
• Timothy E Morris,
  Chief Financial Officer
• Jane Wright Mitchell,
  Chief Legal Officer
• Advisors Llcedelman Josephp...,
  
• John G. Saia,
  General Counsel and Secretary
• Marina Bozilenko,
  Director
• David Chung,
  Chief Commercial Officer
• Venture Partners Qualified ...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• James H Welch,
  Chief Financial Officer
• Thomas A Schreck,
  Director
• Guy P Nohra,
  Director
• Mark Ajaeger Wilfred Ethree...,
  
• Venture Partners Qualified ...,
  
• Richard King,
  President and CEO
• Arch Management Iii Llcwan ...,
  
• Arch Management Iv, L.L.C.T...,
  
• Iv, L.P.Nohra Guy Pjanney D...,
  
• Mark Ajaeger Wilfred Ethree...,
  
• Jill Marie Broadfoot,
  Director